Phytocompounds as potential inhibitors of SARS-CoV-2 Mpro and PLpro through computational studies.

Molecular docking Molecular dynamics Mpro PLpro SARS-CoV-2 Spice phytochemicals

Journal

Saudi journal of biological sciences
ISSN: 1319-562X
Titre abrégé: Saudi J Biol Sci
Pays: Saudi Arabia
ID NLM: 101543796

Informations de publication

Date de publication:
May 2022
Historique:
received: 05 01 2022
revised: 04 02 2022
accepted: 20 02 2022
pubmed: 3 3 2022
medline: 3 3 2022
entrez: 2 3 2022
Statut: ppublish

Résumé

The inhibition of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro) and papain-like protease (PLpro) prevents viral multiplications; these viral enzymes have been recognized as one of the most favorable targets for drug discovery against SARS-CoV-2. In the present study, we screened 225 phytocompounds present in 28 different Indian spices to identify compounds as potential inhibitors of SARS-CoV-2 Mpro and PLpro. Molecular docking, molecular dynamics simulation, molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) binding free energy calculations, and absorption, distribution, metabolism, excretion and toxicity (ADMET) studies were done. Based on binding affinity, dynamics behavior, and binding free energies, the present study identifies pentaoxahexacyclo-dotriacontanonaen-trihydroxybenzoate derivative (PDT), rutin, and dihyroxy-oxan-phenyl-chromen-4-one derivative (DOC), luteolin-7-glucoside-4'-neohesperidoside as promising inhibitors of SARS-CoV-2 Mpro and PLpro, respectively.

Identifiants

pubmed: 35233172
doi: 10.1016/j.sjbs.2022.02.028
pii: S1319-562X(22)00104-8
pmc: PMC8873046
doi:

Types de publication

Journal Article

Langues

eng

Pagination

3456-3465

Informations de copyright

© 2022 The Author(s).

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Mithun Rudrapal (M)

Department of Pharmaceutical Chemistry, Rasiklal M. Dhariwal Institute of Pharmaceutical Education & Research, Pune 411019, Maharashtra, India.

Ismail Celik (I)

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Erciyes University, Kayseri 38280, Turkey.

Sampath Chinnam (S)

Department of Chemistry, M. S. Ramaiah Institute of Technology (Affiliated to Visvesvaraya Technological University, Belgaum), Bengaluru 560054, Karnataka, India.

Mohammad Azam Ansari (M)

Department of Epidemic Disease Research, Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia.

Johra Khan (J)

Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Majmaah University, Al Majmaah 11952, Saudi Arabia.
Health and Basic Sciences Research Center, Majmaah University, Al Majmaah 11952, Saudi Arabia.

Saad Alghamdi (S)

Laboratory Medicine Department, Faculty of Applied Medical Sciences, Um Al-Qura University, Makkah 24382, Saudi Arabia.

Mazen Almehmadi (M)

Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif 21944, Saudi Arabia.

James H Zothantluanga (JH)

Department of Pharmaceutical Sciences, Faculty of Science and Engineering, Dibrugarh University, Dibrugarh 786004, Assam, India.

Shubham J Khairnar (SJ)

MET Institute of Pharmacy, Bhujbal Knowledge City, Nasik 422003, Maharashtra, India.

Classifications MeSH